Fiserv
Conversion Director
Fiserv
Director of Conversions
Education:
Westminster College (Pa) Jan 1, 1982 - Dec 31, 1986
Skills:
Process Improvement Business Process Improvement Requirements Analysis Sdlc Business Analysis Crm Software Project Management Project Management Vendor Management Program Management Leadership Ms Project Management Requirements Gathering Integration
Upmc Nov 1999 - Nov 2012
Registered Nurse
Allegheny General Hospital May 1992 - Nov 1999
Registered Nurse
Pcg Public Partnerships May 1992 - Nov 1999
Personnel Assistant
Education:
University of Pittsburgh - School of Nursing 1988 - 1992
Bachelor of Science In Nursing, Bachelors, Nursing
University of Pitt
Skills:
Patient Advocacy Medical/Surgical Clinical Research Home Care Oncology Healthcare Management Healthcare Managed Care Radiation Oncology Medical Coding Bls Hematology Nursing Education Nursing Inpatient Radiation Therapy Hospitals
heres very little that we can do to combat this virus. And being able to participate in this trial has given me a sense of, that Im doing something, Jennifer Haller of Seattle told the AP. Be prepared for a lot of questions from your friends and family about how its going, and a lot of thank-yo
There's very little that we can do to combat this virus. And being able to participate in this trial has given me a sense of, that I'm doing something," Jennifer Haller of Seattle told the AP. "Be prepared for a lot of questions from your friends and family about how it's going, and a lot of thank-
Date: Jul 27, 2020
Category: More news
Source: Google
First coronavirus trial patient says she's 'proud to help'
Jennifer Haller, 44, heard about the experiment through a Facebook post and thought to herself maybe there is something I could do to contribute to the global fight against the pandemic which has infected 1.5 million people and killed more than 80,000.
On March 16, Jennifer Haller became the first person outside of China to receive a coronavirus vaccine. Developed by Moderna, a well-financed biotech company in the U.S., the vaccine candidate contains a portion of the virus genetic code that does not cause disease, allowing the hosts cells to dev